price month
follow-up convers celgen ir
bottom line receiv mani inbound call potenti risk
ex-u revlimid sale potenti impact bristol/celgen deal
follow alvogen announc launch first gener revlimid
central european countri global later year
opportun follow celgen investor relat
compani continu see low probabl materi risk ex-u
revlimid sale near term
impact alvogen guidanc settlement
alvogen celgen street believ fact celgen fulli
sanction alvogen launch gener revlimid central
eastern european market smaller market licens
deal confidenti term compani provid
addit color compani note countri either
strong intellectu properti enforc ip protect result
licens celgen expect gener revlimid region
bake impact believ immateri guidanc
expect european gener entri europ composit
matter patent expir accord start lawsuit seek
revok uk patent revlimid celgen settl accord
allow gener compani enter market januari uk
februari broader major eu market
trial canada dr reddi submit abbrevi new drug
submiss canada minist celgen su
court hear dr reddi slate sept
higher revlimid dose sept
lowest dose trial natco start march
canada make global revlimid sale
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
compani mention price
